Raymond James analyst Steven Seedhouse made no change to the firm’s Strong Buy rating on 89Bio (ETNB) after Akero (AKRO) reported a week 96 update for its Phase 2b HARMONY study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3. The firm views Akero’s update as positive for 89Bio, whose drug previously showed biomarker stabilization from weeks 24-48, the analyst tells investors in a research note. 89Bio is running a pivotal compensated cirrhosis Nonalcoholic Steatohepatitis study with an interim 2-year histology assessment to form the basis for accelerated approval, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89Bio Inc Is Worried About This – Should You Be Worried Too?
- 89bio price target lowered to $31 from $32 at H.C. Wainwright
- 89bio reports Q4 EPS (50c), consensus (49c)
- 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Madrigal opportunity in MASH remains after Boehringer data, says UBS
